PT  - JOURNAL ARTICLE
AU  - TOSHIHARU MURAKAMI
AU  - TSUTOMU NAKAZAWA
AU  - ATSUSHI NATSUME
AU  - FUMIHIKO NISHIMURA
AU  - MITSUTOSHI NAKAMURA
AU  - RYOSUKE MATSUDA
AU  - KOJI OMOTO
AU  - YOSHITAKA TANAKA
AU  - YOUICHI SHIDA
AU  - YOUNG-SOO PARK
AU  - YASUSHI MOTOYAMA
AU  - ICHIRO NAKAGAWA
AU  - SHUICHI YAMADA
AU  - KENTARO TAMURA
AU  - YASUHIRO TAKESHIMA
AU  - YOSHIAKI TAKAMURA
AU  - TOSHIHIKO WAKABAYASHI
AU  - HIROYUKI NAKASE
TI  - Novel Human NK Cell Line Carrying CAR Targeting EGFRvIII Induces Antitumor Effects in Glioblastoma Cells
AID  - 10.21873/anticanres.12824
DP  - 2018 Sep 01
TA  - Anticancer Research
PG  - 5049--5056
VI  - 38
IP  - 9
4099  - http://ar.iiarjournals.org/content/38/9/5049.short
4100  - http://ar.iiarjournals.org/content/38/9/5049.full
SO  - Anticancer Res2018 Sep 01; 38
AB  - Background/Aim: Natural killer (NK) cells are considered potential antitumor effector cells. The aim of this study was to establish a novel type of a chimeric antigen receptor (CAR) NK cell line (CAR-KHYG-1) specific for epidermal growth factor receptor variant III (EGFRvIII)-expressing tumors and investigate the anti-tumor activity of EGFRvIII-specific-CAR-KHYG-1 (EvCAR-KHYG-1). Materials and Methods: EvCAR-KHYG-1 was established by self-inactivated lentiviral-based transduction of the EvCAR gene and magnetic bead-based purification of EvCAR-expressing NK cells. The anti-tumor effects of EvCAR-KHYG-1 were evaluated using growth inhibition and apoptosis detection assays in glioblastoma (GBM) cell lines (EGFRvIII-expressing and non-expressing U87MG). Results: The findings demonstrated that EvCAR-KHYG-1 inhibited GBM cell-growth via apoptosis in an EGFRvIII-expressing specific manner. Conclusion: This is the first study to establish a CAR NK cell line based on the human NK cell line KHYG-1. Therapy with EvCAR-KHYG-1 may be an effective treatment option for GBM patients.